Last reviewed · How we verify
diphenylcyclopropenone (DPCP)
Diphenylcyclopropenone (DPCP) is a contact sensitizer that triggers a delayed-type hypersensitivity reaction to stimulate immune-mediated hair growth in alopecia.
Diphenylcyclopropenone (DPCP) is a contact sensitizer that triggers a delayed-type hypersensitivity reaction to stimulate immune-mediated hair growth in alopecia. Used for Alopecia areata.
At a glance
| Generic name | diphenylcyclopropenone (DPCP) |
|---|---|
| Also known as | Diphencyprone, DCP |
| Sponsor | Ain Shams University |
| Drug class | Contact sensitizer / Immunostimulant |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
DPCP works by inducing a controlled allergic contact dermatitis on the scalp, which activates T-cell mediated immunity and shifts the hair cycle from telogen (resting) back to anagen (growth) phase. The mechanism is thought to involve local immune activation that suppresses the autoimmune attack on hair follicles in alopecia areata, or directly stimulates follicle activity through inflammatory signaling.
Approved indications
- Alopecia areata
Common side effects
- Contact dermatitis / localized eczema
- Pruritus
- Erythema
- Lymphadenopathy
Key clinical trials
- Diphencyprone Plus Immune Checkpoint Inhibition in the Treatment of Cutaneous Metastases (PHASE1)
- DPCP for the Treatment of Alopecia Areata (PHASE3)
- Trem-1 and Ultraviolet Radiation-induced Immune Suppression (EARLY_PHASE1)
- DPCP to Treat Cutaneous Neurofibromas Associated With NF1 (PHASE1)
- Diphenylcyclopropenone (DPCP) as a Depigmenting Therapy in Extensive Vitiligo (PHASE4)
- Characterization of the Molecular Mechanisms Involved in Delayed-Type Hypersensitivity Reactions to House Dust Mite, Diphencyprone, Nickel, and Tuberculin Purified Protein Derivative in Healthy Volunteers (NA)
- Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP) (PHASE1)
- Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- diphenylcyclopropenone (DPCP) CI brief — competitive landscape report
- diphenylcyclopropenone (DPCP) updates RSS · CI watch RSS
- Ain Shams University portfolio CI